Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Keye

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Scientific Reports|October 25, 2024
Visual and ocular surface benefits of mini-scleral contact lenses in patients with chronic ocular graft-versus-host disease (GvHD)Philip Keye, Susanne Issleib, Yvonne Gier, et al.
Journal of Clinical Medicine|August 12, 2023
XEN<sup>®</sup>-63 Compared to XEN<sup>®</sup>-45 Gel Stents to Reduce Intraocular Pressure in GlaucomaCharlotte Evers, Daniel Böhringer, Sara Kallee, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 19, 2023
XEN<sup>®</sup>-45 implantation for refractory uveitic glaucomaCharlotte Evers, Alexandra Anton, Daniel Böhringer, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|March 6, 2025
Impact of the COVID-19 pandemic on glaucoma surgery in German hospitalsPhilip Keye, Charlotte Evers, Timothy Gläser, et al.
Molecular Oncology|January 20, 2020
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AMLSilvia Waldeck, Michael Rassner, Philip Keye, et al.
Leukemia|November 9, 2021
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AMLAnne Charlet, Max Kappenstein, Philip Keye, et al.
Cancer Cell|February 11, 2025
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunityLukas M Braun, Sophie Giesler, Geoffroy Andrieux, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Scientific Reports|October 25, 2024
Visual and ocular surface benefits of mini-scleral contact lenses in patients with chronic ocular graft-versus-host disease (GvHD)Philip Keye, Susanne Issleib, Yvonne Gier, et al.
Journal of Clinical Medicine|August 12, 2023
XEN<sup>®</sup>-63 Compared to XEN<sup>®</sup>-45 Gel Stents to Reduce Intraocular Pressure in GlaucomaCharlotte Evers, Daniel Böhringer, Sara Kallee, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 19, 2023
XEN<sup>®</sup>-45 implantation for refractory uveitic glaucomaCharlotte Evers, Alexandra Anton, Daniel Böhringer, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|March 6, 2025
Impact of the COVID-19 pandemic on glaucoma surgery in German hospitalsPhilip Keye, Charlotte Evers, Timothy Gläser, et al.
Molecular Oncology|January 20, 2020
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AMLSilvia Waldeck, Michael Rassner, Philip Keye, et al.
Leukemia|November 9, 2021
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AMLAnne Charlet, Max Kappenstein, Philip Keye, et al.
Cancer Cell|February 11, 2025
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunityLukas M Braun, Sophie Giesler, Geoffroy Andrieux, et al.
Pageof 2